NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

GMAB

Genmab ADR

Jul 11 • 04:00PM ET

21.40

Dollar change -0.46
Percentage change -2.10	%

Healthcare • Biotechnology • Denmark • NASD

Peers: AZN JNJ BMY GSK LLY PFE MRK NVS REGN AMGN

| Held by: IBB FBT AVDE FENI CANC FTQI APIE DFAI AVIV DFIV

Scroll to Statements

Index	-	P/E	12.14	EPS (ttm)	1.76	Insider Own	0.00%	Shs Outstand	635.50M	Perf Week	5.42%
Market Cap	13.16B	Forward P/E	11.81	EPS next Y	1.81	Insider Trans	-	Shs Float	615.07M	Perf Month	-6.30%
Enterprise Value	10.08B	PEG	1.22	EPS next Q	0.39	Inst Own	10.62%	Short Float	0.28%	Perf Quarter	13.65%
Income	1.13B	P/S	4.07	EPS this Y	-9.17%	Inst Trans	-0.29%	Short Ratio	1.21	Perf Half Y	-3.52%
Sales	3.23B	P/B	2.57	EPS next Y	18.18%	ROA	19.07%	Short Interest	1.75M	Perf YTD	2.54%
Book/sh	8.33	P/C	4.08	EPS next 5Y	9.92%	ROE	22.69%	52W High	28.56 -25.07%	Perf Year	-16.54%
Cash/sh	5.25	P/FCF	11.30	EPS past 3/5Y	34.34% 28.01%	ROIC	20.91%	52W Low	17.24 24.17%	Perf 3Y	-35.74%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	32.30% 31.15%	Gross Margin	95.12%	Volatility	1.92% 1.71%	Perf 5Y	-37.54%
Dividend TTM	-	EV/Sales	3.12	EPS Y/Y TTM	46.46%	Oper. Margin	33.28%	ATR (14)	0.48	Perf 10Y	177.49%
Dividend Ex-Date	-	Quick Ratio	5.32	Sales Y/Y TTM	25.11%	Profit Margin	35.11%	RSI (14)	52.83	Recom	1.70
Dividend Gr. 3/5Y	- -	Current Ratio	5.34	EPS Q/Q	3.88%	SMA20	0.60%	Beta	0.95	Target Price	31.23
Payout	0.00%	Debt/Eq	0.03	Sales Q/Q	18.64%	SMA50	1.67%	Rel Volume	0.86	Prev Close	21.86
Employees	2682	LT Debt/Eq	0.02	Earnings	May 08 BMO	SMA200	0.70%	Avg Volume	1.45M	Price	21.40
IPO	Jun 01, 2009	Option/Short	Yes / Yes	EPS/Sales Surpr.	29.84% -2.92%	Trades		Volume	1,247,549	Change	-2.10%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-01-25	Downgrade	Bernstein	Mkt Perform → Underperform
Mar-11-25	Upgrade	William Blair	Mkt Perform → Outperform
Feb-13-25	Upgrade	Leerink Partners	Market Perform → Outperform	$27
Oct-08-24	Initiated	Redburn Atlantic	Buy
Sep-04-24	Resumed	Morgan Stanley	Equal-Weight	$31
Aug-20-24	Downgrade	JP Morgan	Overweight → Neutral
Jul-15-24	Upgrade	RBC Capital Mkts	Sector Perform → Outperform
Feb-23-24	Upgrade	BMO Capital Markets	Market Perform → Outperform	$46 → $48
Jan-22-24	Downgrade	Citigroup	Neutral → Sell
Dec-06-23	Upgrade	UBS	Neutral → Buy
Nov-10-23	Upgrade	Deutsche Bank	Hold → Buy
Nov-08-23	Upgrade	DNB Markets	Sell → Buy
Oct-18-23	Initiated	Exane BNP Paribas	Underperform
Sep-06-23	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
Aug-24-23	Initiated	BTIG Research	Buy	$44
Jul-14-23	Initiated	HSBC Securities	Buy
May-31-23	Initiated	UBS	Neutral
May-12-23	Initiated	Morgan Stanley	Underweight
Dec-20-22	Downgrade	Citigroup	Buy → Neutral
Nov-14-22	Initiated	William Blair	Mkt Perform

Show Previous Ratings

Jul-10-25 11:14AM	UBS Maintains a Buy on Genmab (GMAB) With a DKK2,500 PT (Insider Monkey)
08:08AM	Genmab (GMAB) Announced Results From its EPCORE NHL-2 Trial (Insider Monkey)
Jul-03-25 08:19AM	M.Stanley takes neutral stance on Genmab ahead of portfolio, execution updates (Investing.com)
Jul-01-25 08:00AM	Genmab Announces Changes to its Executive Committee (GlobeNewswire)
Jun-30-25 09:30AM	Completion of Share Buy-back Program (GlobeNewswire)
08:19AM	Loading…
Jun-23-25 08:19AM	Transactions in Connection with Share Buy-back Program (GlobeNewswire)
Jun-17-25 01:34PM	Capital Increase in Genmab as a Result of Employee Warrant Exercise (GlobeNewswire)
11:37AM	Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons (GlobeNewswire)
Jun-16-25 09:28AM	Transactions in Connection with Share Buy-back Program (GlobeNewswire)
Jun-15-25 05:00AM	Genmab Announces Epcoritamab Investigational Combination Therapy Demonstrates High Response Rates in Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) Eligible for Autologous Stem Cell Transplantation (ASCT) (GlobeNewswire)
Jun-12-25 01:08PM	Grant of Restricted Stock Units and Warrants to Employees in Genmab (GlobeNewswire)
Jun-10-25 07:23AM	Transactions in Connection with Share Buy-back Program (GlobeNewswire)
Jun-02-25 06:49PM	Why Genmab Stock Smashed It on Monday (Motley Fool)
02:30PM	Genmab Announces Investigational Rinatabart Sesutecan (Rina-S®) Demonstrates Encouraging Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer in Phase 1/2 RAINFOL-01 Trial (GlobeNewswire)
08:03AM	Transactions in Connection with Share Buy-back Program (GlobeNewswire)
02:14PM	Loading…
May-31-25 02:14PM	Morningstar \| A Weekly Summary of Stock Ideas and Developments in the Companies We Cover (Morningstar Research)
May-30-25 09:05AM	Genmab price target lowered to DKK 2,000 from DKK 2,300 at RBC Capital (TipRanks)
May-27-25 09:55AM	Genmab to Participate in a Fireside Chat at the 46th Goldman Sachs Annual Global Healthcare Conference (GlobeNewswire)
May-26-25 08:30AM	Transactions in Connection with Share Buy-back Program (GlobeNewswire)
May-23-25 01:49AM	Genmab A/S (GMAB) Unveils Promising Rina-S and Epcoritamab Data at ASCO 2025 (Insider Monkey)
May-22-25 05:05PM	Genmab to Highlight New Data Evaluating Late-Stage Oncology Portfolio at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting (Business Wire)
May-21-25 10:02AM	Genmab to Participate in a Fireside Chat at the 2025 Jefferies Global Health Care Conference (GlobeNewswire)
May-20-25 12:01PM	Capital Increase in Genmab as a Result of Employee Warrant Exercise (GlobeNewswire)
May-19-25 09:08AM	Transactions in Connection with Share Buy-back Program (GlobeNewswire)
May-14-25 10:15AM	Genmab to Present New and Updated Results from its Robust Epcoritamab (EPKINLY) Development Program at the 2025 European Hematology Association (EHA) Congress (Business Wire)
May-12-25 08:51AM	Transactions in Connection with Share Buy-back Program (GlobeNewswire)
May-08-25 11:01AM	Genmab Announces Financial Results for the First Quarter of 2024 (GlobeNewswire) -5.73%
May-05-25 08:23AM	Transactions in Connection with Share Buy-back Program (GlobeNewswire)
May-01-25 08:24PM	Genmab to Submit Supplemental Biologics License Application (sBLA) to U.S. Food and Drug Administration for Epcoritamab Plus Rituximab and Lenalidomide (R2) in Patients with Relapsed/Refractory Follicular Lymphoma (FL) (Business Wire)
03:31AM	Is Genmab A/S (GMAB) the Most Profitable Growth Stock to Buy Now? (Insider Monkey)
08:16AM	Loading…
Apr-28-25 08:16AM	Transactions in Connection with Share Buy-back Program (GlobeNewswire)
Apr-27-25 11:40PM	Why AbbVie's Stock Is A Strong Buy After Q1 2025 Results (Seeking Alpha)
Apr-24-25 07:46AM	Johnson & Johnson Just Proved The Bears Wrong Again (Seeking Alpha)
Apr-22-25 07:23AM	Transactions in Connection with Share Buy-back Program (GlobeNewswire)
Apr-20-25 11:28AM	IDNA: The Cutting Edge Of Medical Science Is A Risky Investment (Seeking Alpha)
Apr-16-25 11:40AM	GMAB or RGEN: Which Is the Better Value Stock Right Now? (Zacks)
09:40AM	Should Value Investors Buy Genmab (GMAB) Stock? (Zacks)
Apr-15-25 07:36AM	Genmab's Outlook Beyond Darzalex's Patent Cliff (Seeking Alpha)
06:22AM	Genmab Announces Net Sales of DARZALEX (daratumumab) for First Quarter of 2025 (GlobeNewswire)
Apr-14-25 08:42AM	Transactions in Connection with Share Buy-back Program (GlobeNewswire)
Apr-10-25 12:20PM	Genmab A/S Share Capital Reduction (GlobeNewswire)
Apr-07-25 07:43AM	Transactions In Connection with Share Buy-back Program (GlobeNewswire)
Apr-02-25 09:47AM	Is Genmab A/S (GMAB) d The Most Profitable Biotech Stock To Buy Right Now? (Insider Monkey)
Apr-01-25 03:53PM	Transactions With Shares and Linked Securities in Genmab A/S Made by Managerial Employees and Their Closely Associated Persons (GlobeNewswire)
10:00AM	Is Genmab A/S (GMAB) the Most Undervalued Healthcare Stock to Buy According to Analysts? (Insider Monkey)
Mar-31-25 11:20AM	TIVDAK (tisotumab vedotin) Approved by European Commission for Previously Treated Recurrent or Metastatic Cervical Cancer (GlobeNewswire)
08:18AM	Transactions in connection with share buy-back program (GlobeNewswire)
Mar-27-25 08:00AM	TIVDAK (tisotumab vedotin) Approved by Japan Ministry of Health, Labour and Welfare for the Treatment of Advanced or Recurrent Cervical Cancer that has Progressed on or after Chemotherapy (Business Wire)
Mar-25-25 05:28PM	Genmab Announces Initiation of Share Buy-Back Program (GlobeNewswire)
Mar-21-25 11:29PM	Genmab to Vigorously Defend Alleged Claims of Trade Secret Misappropriation by AbbVie Inc. (GlobeNewswire)
Mar-17-25 12:19PM	Investigational Rinatabart Sesutecan (Rina-S®) Continues to Show Encouraging Antitumor Activity in Patients with Advanced Ovarian Cancer (GlobeNewswire)
Mar-12-25 02:19PM	Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons (GlobeNewswire)
02:13PM	Constitution of the Board of Directors in Genmab A/S, Grant of Restricted Stock Units to Board Members and Employees and Grant of Warrants to Employees in Genmab (GlobeNewswire)
10:23AM	Passing of Genmab A/S Annual General Meeting (GlobeNewswire)
Mar-11-25 10:20AM	Genmab says J&J not exercising option on HexaBody-CD38 (TipRanks) -7.80%
Mar-10-25 10:21AM	Genmab Announces Johnson & Johnson Decision Regarding HexaBody-CD38 (Business Wire) -8.97%
Mar-04-25 11:58AM	Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons (GlobeNewswire)
Feb-28-25 04:04PM	Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons (GlobeNewswire)
04:00PM	Grant of Restricted Stock Units to Management and Employees and Grant of Warrants to Employees in Genmab (GlobeNewswire)
Feb-25-25 03:32PM	Genmab A/S (GMAB): Among the Stocks That Will Go to the Moon According to Analysts (Insider Monkey)
02:30PM	Capital Increase in Genmab as a Result of Employee Warrant Exercise (GlobeNewswire)
Feb-20-25 08:00AM	EPKINLY (epcoritamab) Approved by Japan Ministry of Health, Labour and Welfare for Additional Indication as a Treatment for Relapsed or Refractory Follicular Lymphoma (Business Wire)
Feb-19-25 09:14AM	Genmab to Participate in a Fireside Chat at the 45th Annual TD Cowen Health Care Conference (GlobeNewswire)
Feb-13-25 06:00AM	Notice to Convene the Annual General Meeting of Genmab A/S (GlobeNewswire) +6.25%
Feb-12-25 01:14PM	Genmab Files Annual Report with the U.S. Securities and Exchange Commission (GlobeNewswire)
11:01AM	Genmab Publishes 2024 Annual Report (GlobeNewswire)
Jan-23-25 03:08PM	Grant of Restricted Stock Units and Warrants to Employees in Genmab (GlobeNewswire)
Jan-22-25 06:23AM	Genmab Announces Net Sales of DARZALEX® (daratumumab) for 2024 (GlobeNewswire)
Jan-03-25 01:56PM	Genmab to Present at the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-11-24 08:20AM	Genmab to Hold 2024 RandD Update and ASH Data Review Meeting (GlobeNewswire)
08:20AM	Genmab to Hold 2024 R&D Update and ASH Data Review Meeting (GlobeNewswire)
Dec-09-24 12:00PM	Two Data Analyses from Clinical Trials Show Epcoritamab (DuoBody CD3xCD20) Induces Durable, Complete Responses as Monotherapy and Combination Treatment in Patients With Diffuse Large B-Cell Lymphoma (DLBCL) (Business Wire)
Dec-08-24 11:00AM	Investigational Epcoritamab (DuoBody® CD3xCD20) Monotherapy Achieves High Overall and Complete Response Rates in Clinical Trial of Patients With Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) in Preliminary Analysis (Business Wire)
Dec-07-24 07:12PM	Investigational Epcoritamab (DuoBody® CD3xCD20) Combination Therapy Demonstrates High Response Rates in Clinical Trial of Patients With Relapsed or Refractory (R/R) Follicular Lymphoma (FL) (GlobeNewswire)
Dec-03-24 04:35PM	Capital Increase in Genmab as a Result of Employee Warrant Exercise (GlobeNewswire)
07:07AM	Transactions With Shares and Linked Securities in Genmab A/S Made by Managerial Employees and Their Closely Associated Persons (GlobeNewswire)
Nov-25-24 11:06AM	Genmab to Present at Citi's Global Healthcare Conference (GlobeNewswire)
Nov-21-24 02:48PM	Grant of Restricted Stock Units and Warrants to Employees in Genmab (GlobeNewswire)
Nov-06-24 11:02AM	Genmab Announces Financial Results for the First Nine Months of 2024 (GlobeNewswire)
Nov-05-24 01:11PM	Genmab to Present at Jefferies London Healthcare Conference (GlobeNewswire)
12:00PM	Genmab to Showcase Strength and Breadth of Comprehensive Epcoritamab-bysp Development Program at 2024 American Society of Hematology (ASH) Annual Meeting (GlobeNewswire)
Oct-17-24 08:57AM	Genmab A/S (GMAB): Leading Innovation in Antibody Therapeutics (Insider Monkey)
Oct-16-24 09:44AM	Is the Options Market Predicting a Spike in Genmab (GMAB) Stock? (Zacks)
Oct-15-24 09:40AM	Is Genmab (GMAB) Stock Undervalued Right Now? (Zacks)
06:25AM	Genmab Announces Net Sales of DARZALEX (daratumumab) for Third Quarter of 2024 (GlobeNewswire)
Oct-04-24 01:55PM	Major Shareholder Announcement (GlobeNewswire)
Sep-26-24 03:17PM	Grant of Restricted Stock Units and Warrants to Employees in Genmab (GlobeNewswire)
Sep-15-24 08:45AM	Investigational Rinatabart Sesutecan (Rina-S) Shows Promising Anti-Tumor Activity as Single Agent in Heavily Pretreated Patients with Ovarian and Endometrial Cancers in Phase 1/2 Clinical Trial (Business Wire)
Sep-10-24 04:06PM	Capital Increase in Genmab as a Result of Employee Warrant Exercise (GlobeNewswire)
Aug-30-24 05:49PM	Genmab A/S (GMAB): One of the Best Affordable Stocks Under $40 According to Short Sellers (Insider Monkey)
Aug-26-24 12:26PM	Genmab to Present at Morgan Stanley 22nd Annual Global Healthcare Conference (GlobeNewswire)
Aug-19-24 02:00PM	TEPKINLY (epcoritamab) Receives Second European Commission Approval for the Treatment of Adults with Relapsed/Refractory Follicular Lymphoma (GlobeNewswire)
Aug-16-24 09:00AM	Genmab Announces Changes to its Executive Committee (Business Wire)
Aug-13-24 02:53PM	Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons (GlobeNewswire)
02:51PM	Capital Increase in Genmab as a Result of Employee Warrant Exercise (GlobeNewswire)
Aug-08-24 11:03AM	Genmab Announces Financial Results for the First Half of 2024 (GlobeNewswire)
11:00AM	Genmab Updates 2024 Financial Guidance (GlobeNewswire)
Aug-05-24 05:50AM	Genmab Takes Full Control of Acasunlimab Development Program (GlobeNewswire) -7.68%
Jul-17-24 06:25AM	Genmab Announces Net Sales of DARZALEX (daratumumab) for Second Quarter of 2024 (GlobeNewswire)
Jun-28-24 02:00AM	Epcoritamab (TEPKINLY) Receives Positive CHMP Opinion for the Treatment of Adults with Relapsed/ Refractory Follicular Lymphoma (Business Wire)

Genmab A/S is an international biotechnology company, which engages in the development of human antibody therapeutics for the treatment of cancer and other diseases. Its product pipeline includes daratumumab, marketed as DARZALEX for the treatment of certain indications of multiple myeloma, teprotumumab-trbw marketed as TEPEZZA for the treatment of thyroid eye disease, and ofatumumab, marketed as Arzerra for the treatment of certain indications of chronic lymphocytic leukemia. The company was founded by Donald Lee Drakeman, Florian Schonharting, and Jan G. J. van de Winkel on June 11, 1998, and is headquartered in Copenhagen, Denmark.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Klimovsky Judith V	Director	Jun 17 '25	Proposed Sale	51.69	1,300	67,200		Jun 17 02:30 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

GMAB

Genmab ADR

Upgrade your FINVIZ experience